SAN DIEGO, Calif. – By Lee Han-soo/Korea Biomedical Review correspondent -- The 65th American Society of Hematology (ASH) opened the world's largest hematology conference in San Diego, Calif, the U.S., on Saturday.

The American Society of Hematology's official mascot Red waves his hands to participants during the conference.
The American Society of Hematology's official mascot Red waves his hands to participants during the conference.

According to the organizers, the exhibition will be participated by 275 exhibitors and saw record-breaking attendance figures with 32,000 in-person and 5,000 virtual attendees.

The conference also saw over 7,400 abstract submissions, of which 1,068 will be presented orally.

Notably, experts in hematology anticipate that this year's conference will delve into various topics, encompassing the evolving treatment landscape for chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML), as well as addressing CAR-T safety and sickle cell disease.

Korea Biomedical Review captured some of the scenes and booths of companies exhibiting at the ASH 2023 meeting. ASH 2023 is open from Saturday to next Tuesday, at the San Diego Convention Center.

Hematology experts and companies gathered in San Diego to attend the American Society of Hematology 2023 Conference, a hub of medical innovation and research in the field of hematology. The conference will run from Saturday to Tuesday at the San Diego Convention Center in San Diego, Calif.
Hematology experts and companies gathered in San Diego to attend the American Society of Hematology 2023 Conference, a hub of medical innovation and research in the field of hematology. The conference will run from Saturday to Tuesday at the San Diego Convention Center in San Diego, Calif.

 

Novartis has made significant strides in the field of blood cancer treatment over the years. During this year’s conference, Novartis will likely showcase its latest research, including CAR-T treatments, and engage with the medical community.
Novartis has made significant strides in the field of blood cancer treatment over the years. During this year’s conference, Novartis will likely showcase its latest research, including CAR-T treatments, and engage with the medical community.
BeiGene will highlight its hematology portfolio, featuring data on the efficacy of BRUKINSA and promising results from its pipeline, including sonrotoclax and the novel BTK degrader BGB-16673. With 24 abstracts, including three oral presentations, BeiGene emphasizes its innovation in blood cancer therapies and its commitment to improving patient outcomes.
BeiGene will highlight its hematology portfolio, featuring data on the efficacy of BRUKINSA and promising results from its pipeline, including sonrotoclax and the novel BTK degrader BGB-16673. With 24 abstracts, including three oral presentations, BeiGene emphasizes its innovation in blood cancer therapies and its commitment to improving patient outcomes.

 

AstraZeneca will feature 63 abstracts on hematological therapies, including Calquence's long-term efficacy in CLL, the potential of new modalities like AZD0486 for lymphoma, and advances in PNH treatment with Factor D inhibitors. Data will also show Ultomiris' impact on survival in PNH and provide updates on rare disease management including amyloidosis.
AstraZeneca will feature 63 abstracts on hematological therapies, including Calquence's long-term efficacy in CLL, the potential of new modalities like AZD0486 for lymphoma, and advances in PNH treatment with Factor D inhibitors. Data will also show Ultomiris' impact on survival in PNH and provide updates on rare disease management including amyloidosis.
Genentech, a subsidiary of Roche, will also unveil various studies related to blood illnesses. Notably, the phase 3 HAVEN 7 study results presented at ASH 2023 demonstrate Hemlibra's efficacy and safety in infants with severe hemophilia A, showing significant bleed control and tolerability. This supports early prophylaxis and offers a practical subcutaneous treatment option, enhancing Hemlibra's role in hemophilia A treatment globally.
Genentech, a subsidiary of Roche, will also unveil various studies related to blood illnesses. Notably, the phase 3 HAVEN 7 study results presented at ASH 2023 demonstrate Hemlibra's efficacy and safety in infants with severe hemophilia A, showing significant bleed control and tolerability. This supports early prophylaxis and offers a practical subcutaneous treatment option, enhancing Hemlibra's role in hemophilia A treatment globally.
AbbVie and its partner Genmab will present promising trial results for epcoritamab in treating relapsed/refractory follicular lymphoma, showing strong patient responses and an improved dosing regimen. With FDA Breakthrough Therapy Designation and an EMA application in progress, they aim to establish epcoritamab as a key treatment for various B-cell malignancies.
AbbVie and its partner Genmab will present promising trial results for epcoritamab in treating relapsed/refractory follicular lymphoma, showing strong patient responses and an improved dosing regimen. With FDA Breakthrough Therapy Designation and an EMA application in progress, they aim to establish epcoritamab as a key treatment for various B-cell malignancies.
Amgen will showcase its hematology portfolio, focusing on Blincyto for acute lymphoblastic leukemia, Kyprolis for multiple myeloma, and a biosimilar candidate to eculizumab for paroxysmal nocturnal hemoglobinuria. These presentations highlight the company's advancements in treatment options for blood cancers and rare hematological conditions.
Amgen will showcase its hematology portfolio, focusing on Blincyto for acute lymphoblastic leukemia, Kyprolis for multiple myeloma, and a biosimilar candidate to eculizumab for paroxysmal nocturnal hemoglobinuria. These presentations highlight the company's advancements in treatment options for blood cancers and rare hematological conditions.
Bristol Myers Squibb will highlight their progress in hematology, featuring key studies on Breyanzi for follicular lymphoma, Abecma for multiple myeloma, and Reblozyl for anemia in myelodysplastic syndromes. They will also present updates on novel therapies like GPRC5D CAR T for multiple myeloma and targeted protein degradation agents, demonstrating their dedication to developing innovative treatments for blood disorders.
Bristol Myers Squibb will highlight their progress in hematology, featuring key studies on Breyanzi for follicular lymphoma, Abecma for multiple myeloma, and Reblozyl for anemia in myelodysplastic syndromes. They will also present updates on novel therapies like GPRC5D CAR T for multiple myeloma and targeted protein degradation agents, demonstrating their dedication to developing innovative treatments for blood disorders.
Takeda will showcase 17 abstracts highlighting key developments in hematologic diseases. This ｉｎｃｌｕｄｅs phase 3 trial results for Adzynma in congenital thrombotic thrombocytopenic purpura (cTTP), phase 1 data for TAK-755 in sickle cell disease, and oncology research in leukemia and lymphoma.
Takeda will showcase 17 abstracts highlighting key developments in hematologic diseases. This ｉｎｃｌｕｄｅs phase 3 trial results for Adzynma in congenital thrombotic thrombocytopenic purpura (cTTP), phase 1 data for TAK-755 in sickle cell disease, and oncology research in leukemia and lymphoma.
Gilead Sciences and its subsidiary Kite will present 29 studies, including significant findings on Yescarta for large B-cell lymphoma and Tecartus in acute lymphoblastic leukemia and mantle cell lymphoma. They'll highlight long-term effectiveness and survival data across various studies and age groups, emphasizing the potential of CAR T-cell therapies in blood cancers. Additionally, phase 1 results for CART-dd BCMA in multiple myeloma will be showcased.
Gilead Sciences and its subsidiary Kite will present 29 studies, including significant findings on Yescarta for large B-cell lymphoma and Tecartus in acute lymphoblastic leukemia and mantle cell lymphoma. They'll highlight long-term effectiveness and survival data across various studies and age groups, emphasizing the potential of CAR T-cell therapies in blood cancers. Additionally, phase 1 results for CART-dd BCMA in multiple myeloma will be showcased.
The conference also provided a variety of programs aimed to help relax or increase the excitement for participants and exhibitors. Such programs ｉｎｃｌｕｄｅd a nap center, checkers, picture spots, and bean bag toss.
The conference also provided a variety of programs aimed to help relax or increase the excitement for participants and exhibitors. Such programs included a nap center, checkers, picture spots, and bean bag toss.

 

Copyright © KBR Unauthorized reproduction, redistribution prohibited